



Food and Drugs Authority Safety Monitoring Department/National Pharmacovigilance Center

Adverse Reaction Reporting Scoreboard

Outlook of Regional Performance

The Safety Monitoring Department of the FDA publishes the Adverse Reaction Reporting Scoreboard bi-monthly to provide quantitative information on training programs and individual case safety reports (ICSRs) from sixteen regions. The objective of this publication is to compare reporting trends in reporting adverse reactions to drugs and vaccines and other health-related products at the regional level to enhance the diagnosis, management, and reporting of safety issues.

It is expected that, the publication will help improve reporting of adverse reactions and detection of new safety signals for vaccines, medicines and other healthcare products. This edition focuses on 2024 mid-year performance of pharmacovigilance activities across the regions.

Pharmacovigilance Training Programs

Between January to June, the FDA had 294 pharmacovigilance (PV) training programs in the 16 regions with a total of 9,399 participants consisting of practicing and student healthcare professionals. In terms of the bi-monthly performance, 87 training programmes were held with 2,427 personnel trained. Considering a mid-year set target of at least 18 PV meetings, the Ashanti region (42) continues to top the chart with the highest number of training programmes held followed by Greater Accra region (41). Figure 1 shows the performance of the regions in terms of the number of PV training programs.




Fig. 1: The number of PV training programs organized in the regions.

Figure 2 shows the percentage of the professional backgrounds of the participants trained during the PV training programs.




Fig. 2: Professional background of participants for the PV training programs in percentage.



Adverse Reactions Reported

By mid-year 2024, one thousand one hundred and thirty-seven (1,137) Individual Case Safet Reports had been received for medicines, vaccines and other health products; this comprises 156 adverse events following immunization (AEFI), 19 product quality issues and 962 adverse drug reactions. The Greater Accra region recorded the highest absolute number of reports (Figure 3). However, the Bono Region had the highest reporting of 9 reports per 100,000 population (Figure 4) based on the 2021 population and housing census; 126 reports were received from the 16 regions between May and June 2024.




Fig. 3. Number of adverse reaction reports received in the region.




Fig. 4: Regional reporting rate per 100,000 population (2021 Population and Housing Census)

You may reach out to the Safety Monitoring Department on the underlisted contacts for information on the safety of medicines, vaccines, blood and blood products, medical devices and other health products:

Telephone : 024 4310 297

Email : drug.safety@fda.gov.gh